Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel. [PDF]
De Stefano V +10 more
europepmc +1 more source
JAK2 is a critical therapeutic target in VEXAS syndrome treated with ruxolitinib. [PDF]
Ceccardi A +17 more
europepmc +1 more source
Correction: Colomba et al. Haemodynamic Forces: Emerging Markers of Ventricular Remodelling in Multiple Myeloma Cardiovascular Baseline Risk Assessment. Cancers 2024, 16, 3081. [PDF]
Colomba A +13 more
europepmc +1 more source
Mismatch Between Preclinical Cardio-Oncology and Clinical Oncology Research. [PDF]
Cagnazzo R +6 more
europepmc +1 more source
Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma. [PDF]
Bonello F +14 more
europepmc +1 more source
New Strategies for the Treatment of Older Myeloma Patients. [PDF]
Larocca A +4 more
europepmc +1 more source
The Emerging Role of Left Atrial Strain in Cardiovascular Risk Stratification for Multiple Myeloma Patients Undergoing Carfilzomib Therapy. [PDF]
Colomba A +13 more
europepmc +1 more source
[Therapeutic alternatives for drug-associated maxillary osteonecrosis (MRONJ): reports of two clinical cases and review of the literature]. [PDF]
Leonardi N +3 more
europepmc +1 more source
Hyperinflammatory Syndrome as a Cardiac Injury Mechanism. [PDF]
Ayub-Ferreira SM, Lira MTSS.
europepmc +1 more source

